Literature DB >> 1611208

Activity of antimicrobial agents against Mycobacterium avium-intracellulare complex (MAC) strains isolated in Italy from AIDS-patients.

L Fattorini1, C Q Hu, S H Jin, C Santoro, A Y Tsang, M T Mascellino, F Mandler, G Orefici.   

Abstract

Twenty-five strains of Mycobacterium avium-intracellulare (MAC) isolated from acquired immunodeficiency syndrome (AIDS) patients in three medical centres in Italy have been studied. Serotyping performed on eighteen strains showed various serovars within either M. avium or M. intracellulare serotypes and with serovars 1 and 21 being the most prevalent (four strains for each serovar). Among fourteen drugs used for testing the antibiotic sensitivity, rifapentine, rifabutin and clofazimine showed to have the best in vitro activity. In an ex vivo model of infection using peritoneal resting macrophages from the C57BL/6 mouse, the intracellular viability of a strain of M. avium (strain 489, serovar 3) was reduced by clofazimine, amikacin, ciprofloxacin, rifabutin and clarithromycin (99, 98, 93, 89 and 69%, respectively), thus indicating for clofazimine a good correlation between in vitro and ex vivo activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611208

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  3 in total

1.  Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice.

Authors:  L Fattorini; Y Xiao; M Mattei; Y Li; E Iona; M L Ricci; O F Thoresen; R Creti; G Orefici
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

2.  In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium.

Authors:  L Fattorini; B Li; C Piersimoni; E Tortoli; Y Xiao; C Santoro; M L Ricci; G Orefici
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 3.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.